APA (7th ed.) Citation

Shell, R., Al-Zaidy, S., Arnold, W., Rodino-Klapac, L., Prior, T., Kotha, K., . . . Mendell, J. (2018). SMA THERAPIES I: P.178AVXS-101 phase 1 gene therapy clinical trial in spinal muscular atrophy type 1: improvement in respiratory and bulbar function reduces frequency and duration of hospitalizations compared to natural history. Neuromuscular Disorders, 28, S82. https://doi.org/10.1016/j.nmd.2018.06.206

Chicago Style (17th ed.) Citation

Shell, R., et al. "SMA THERAPIES I: P.178AVXS-101 Phase 1 Gene Therapy Clinical Trial in Spinal Muscular Atrophy Type 1: Improvement in Respiratory and Bulbar Function Reduces Frequency and Duration of Hospitalizations Compared to Natural History." Neuromuscular Disorders 28 (2018): S82. https://doi.org/10.1016/j.nmd.2018.06.206.

MLA (9th ed.) Citation

Shell, R., et al. "SMA THERAPIES I: P.178AVXS-101 Phase 1 Gene Therapy Clinical Trial in Spinal Muscular Atrophy Type 1: Improvement in Respiratory and Bulbar Function Reduces Frequency and Duration of Hospitalizations Compared to Natural History." Neuromuscular Disorders, vol. 28, 2018, p. S82, https://doi.org/10.1016/j.nmd.2018.06.206.